baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Goldman Sachs Put 900 REGN 17.05..../ DE000GG2N9Z9 /

2024-05-16 10:19:47 AM	Chg.+0.006	Bid10:00:41 PM	Ask10:00:41 PM	Underlying	Strike price	Expiration date	Option type
0.010EUR	+150.00%	- Bid Size: -	- Ask Size: -	Regeneron Pharmaceut...	- USD	2024-05-17	Put

GlobeNewswire 05-14 Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Sci...

GlobeNewswire 05-14 Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer

GlobeNewswire 05-13 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...

GlobeNewswire 05-10 Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire 05-09 Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company P...

GlobeNewswire 05-08 Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound G...

GlobeNewswire 05-07 Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference

GlobeNewswire 05-06 Regeneron Announces Investor Conference Presentations

GlobeNewswire 05-02 Regeneron Reports First Quarter 2024 Financial and Operating Results

GlobeNewswire 04-29 EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Mean...

GlobeNewswire 04-26 Medigene AG reports Financial Results and Business Update for Q1 2024

GlobeNewswire 04-25 Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing fo...

GlobeNewswire 04-24 Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad R...

GlobeNewswire 04-23 Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution

GlobeNewswire 04-22 Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Th...

GlobeNewswire 04-18 Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals,...

GlobeNewswire 04-18 REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Beh...

GlobeNewswire 04-16 Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024

GlobeNewswire 04-16 Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

GlobeNewswire 04-15 Regeneron Ventures Launches with $500 Million Commitment to Fuel Promising Biotechnology Innovation

GlobeNewswire 04-11 INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Phar...

GlobeNewswire 04-09 Opthea Appoints John Han, PharmD, as VP Medical Affairs

GlobeNewswire 04-07 Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in ...

GlobeNewswire 04-01 Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and ...

GlobeNewswire 03-25 Regeneron Provides Update on Biologics License Application for Odronextamab

Goldman Sachs Put 900 REGN 17.05..../ DE000GG2N9Z9 /

If you wish to receive reply to your feedback, please provide your email address.